Yu WB, Rao A, Vu V, Xu L, Rao JY, Wu JX. Management of centrally located hepatocellular carcinoma: Update 2016. World J Hepatol 2017; 9(13): 627-634 [PMID: 28539990 DOI: 10.4254/wjh.v9.i13.627]
Corresponding Author of This Article
Jian-Xiong Wu, MD, Professor, Chief, Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Beijing 100021, China. dr.wujx@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 8, 2017; 9(13): 627-634 Published online May 8, 2017. doi: 10.4254/wjh.v9.i13.627
Management of centrally located hepatocellular carcinoma: Update 2016
Wei-Bo Yu, Andrew Rao, Victor Vu, Lily Xu, Jian-Yu Rao, Jian-Xiong Wu
Wei-Bo Yu, Victor Vu, Jian-Yu Rao, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, United States
Andrew Rao, the College of Letters and Science, University of California at Davis, Davis, CA 95616, United States
Lily Xu, Chemistry Department, Wellesley College, Wellesley, MA 02481, United States
Jian-Xiong Wu, Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Yu WB and Wu JX designed the aim of this review; Yu WB, Rao A and Rao JY prepared the manuscript; Vu V and Xu L critically reviewed the manuscript.
Conflict-of-interest statement: All authors have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jian-Xiong Wu, MD, Professor, Chief, Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Beijing 100021, China. dr.wujx@hotmail.com
Telephone: +86-10-87787100
Received: January 27, 2017 Peer-review started: February 12, 2017 First decision: March 8, 2017 Revised: March 24, 2017 Accepted: April 6, 2017 Article in press: April 10, 2017 Published online: May 8, 2017
Abstract
Centrally located hepatocellular carcinoma (HCC) is sited in the central part of the liver and adjacent to main hepatic vascular structures. This special location is associated with an increase in the difficulty of surgery, aggregation of the recurrence disease, and greater challenge in disease management. This review summarizes the evolution of our understanding for centrally located HCC and discusses the development of treatment strategies, surgical approaches and recurrence prevention methods. To improve patient survival, a multi-disciplinary modality is greatly needed throughout the whole treatment period.
Core tip: Centrally located hepatocellular carcinoma (HCC) is situated in the deeper portions of the liver and adjoins main vascular structures. Due to this special location, the management of this group of patients is challenging. Low resection rates and high recurrence rates are two major problems that urgently need to be resolved. This review summarizes the evolution of our understanding for centrally located HCC and the development of disease management, and explores the possible strategies to improve overall patient survival.
